サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541063

髄膜炎菌ワクチン市場レポート：ワクチンタイプ、組成、ワクチン血清型、流通チャネル、エンドユーザー、地域別、2024～2032年

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 137 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
髄膜炎菌ワクチン市場レポート：ワクチンタイプ、組成、ワクチン血清型、流通チャネル、エンドユーザー、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の髄膜炎菌ワクチン市場規模は2023年に36億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて7.7%の成長率（CAGR）を示し、2032年までに72億米ドルに達すると予測しています。

髄膜炎菌ワクチンとは、脊髄と脳を包む膜の伝染性感染症である髄膜炎の予防のために投与される生物学的物質を指します。髄膜炎菌ワクチンには、結合型、多糖型、被膜下型があります。これらのワクチンは、髄膜炎菌A、B、C、W-135、Yを標的とする侵襲性疾患に対する免疫をつけるために、乳幼児、小児、成人に接種されます。ワクチンが接種されると、細菌と闘う抗体が形成され、将来感染を予防するための免疫反応が生じます。

世界中で幼児や青少年の間で髄膜炎菌性疾患の有病率が増加していることは、市場の成長を促進する重要な要因のひとつです。さらに、大衆の間での健康意識の高まりと定期的な予防接種の採用が、市場の成長を後押ししています。髄膜炎菌ワクチンは、この病気を予防し、一時的または永続的な難聴、視力や運動能力の低下、発作、神経障害などの長期的影響を最小限に抑えるのに役立ちます。これに伴い、先進経済諸国と新興経済諸国の政府は、感染リスクを抑制するために、観光客や軍人などの特別なリスクグループへの予防接種を重視しながら、大規模な公衆衛生プログラムを開始しています。さらに、再構成を必要としないすぐに使える液体製剤の開発など、さまざまな製品革新も市場の成長に寄与しています。その他の要因としては、広範な研究開発（R&D）活動、医療インフラの改善などが挙げられ、市場のさらなる牽引役となることが予想されます。

本レポートで扱う主要質問

  • 世界の髄膜炎菌ワクチン市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19は世界の髄膜炎菌ワクチン市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • ワクチンタイプ別の市場内訳は？
  • 組成別の市場内訳は？
  • ワクチン血清型別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の髄膜炎菌ワクチン市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の髄膜炎菌ワクチン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ワクチンタイプ別

  • 共役
  • 多糖類
  • 被膜下

第7章 市場内訳：組成別

  • 単核ワクチン
  • 混合ワクチン

第8章 市場内訳：ワクチン血清型別

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC
  • その他

第9章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • 機関投資家向け販売
  • その他

第10章 市場内訳：エンドユーザー別

  • 小児科
  • 成人用

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • GlaxoSmithKline Plc
    • Hualan Biological Engineering Inc.
    • Incepta Pharmaceuticals Limited
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Serum Institute of India Ltd.
    • Walvax Biotechnology Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Meningococcal Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Meningococcal Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Meningococcal Vaccines Market: Breakup by Vaccine Type (in %), 2023
  • Figure 4: Global: Meningococcal Vaccines Market: Breakup by Composition (in %), 2023
  • Figure 5: Global: Meningococcal Vaccines Market: Breakup by Vaccine Serotype (in %), 2023
  • Figure 6: Global: Meningococcal Vaccines Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Meningococcal Vaccines Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Meningococcal Vaccines Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Meningococcal Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 10: Global: Meningococcal Vaccines (Conjugate) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Meningococcal Vaccines (Conjugate) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Meningococcal Vaccines (Polysaccharide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Meningococcal Vaccines (Polysaccharide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Meningococcal Vaccines (Subcapsular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Meningococcal Vaccines (Subcapsular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Meningococcal Vaccines (Mono Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Meningococcal Vaccines (Mono Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Meningococcal Vaccines (Combination Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Meningococcal Vaccines (Combination Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Meningococcal Vaccines (MenACWY) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Meningococcal Vaccines (MenACWY) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Meningococcal Vaccines (MenB & Manic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Meningococcal Vaccines (MenB & Manic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Meningococcal Vaccines (MenC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Meningococcal Vaccines (MenC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Meningococcal Vaccines (MenA) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Meningococcal Vaccines (MenA) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Meningococcal Vaccines (MenAC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Meningococcal Vaccines (MenAC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Meningococcal Vaccines (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Meningococcal Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Meningococcal Vaccines (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Meningococcal Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Meningococcal Vaccines (Institutional Sales) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Meningococcal Vaccines (Institutional Sales) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Meningococcal Vaccines (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Meningococcal Vaccines (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Meningococcal Vaccines (Pediatric) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Meningococcal Vaccines (Pediatric) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Meningococcal Vaccines (Adult) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Meningococcal Vaccines (Adult) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: North America: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: North America: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: United States: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: United States: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Canada: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Canada: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Asia Pacific: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Asia Pacific: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: China: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: China: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Japan: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Japan: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: India: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: India: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: South Korea: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: South Korea: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Australia: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Australia: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Indonesia: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Indonesia: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Europe: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Europe: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Germany: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Germany: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: France: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: France: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: United Kingdom: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: United Kingdom: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Italy: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Italy: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Spain: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Spain: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Russia: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Russia: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Latin America: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Latin America: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Brazil: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Brazil: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Mexico: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Mexico: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Middle East and Africa: Meningococcal Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Middle East and Africa: Meningococcal Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Meningococcal Vaccines Industry: SWOT Analysis
  • Figure 93: Global: Meningococcal Vaccines Industry: Value Chain Analysis
  • Figure 94: Global: Meningococcal Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Meningococcal Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Meningococcal Vaccines Market Forecast: Breakup by Composition (in Million US$), 2024-2032
  • Table 4: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Serotype (in Million US$), 2024-2032
  • Table 5: Global: Meningococcal Vaccines Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Meningococcal Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 7: Global: Meningococcal Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Meningococcal Vaccines Market: Competitive Structure
  • Table 9: Global: Meningococcal Vaccines Market: Key Players
目次
Product Code: SR112024A2730

The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.

Meningococcal vaccine refers to a biological substance administered for the prevention of meningitis, which is a contagious infection of the membranes surrounding the spinal cord and the brain. The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines. They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y. Once the vaccine is administered, antibodies are formed to fight the bacteria and create an immune response to prevent the infection in the future.

The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage. In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global meningococcal vaccines market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel and end user.

Breakup by Vaccine Type:

Conjugate

Polysaccharide

Subcapsular

Breakup by Composition:

Mono Vaccines

Combination Vaccines

Breakup by Vaccine Serotype:

MenACWY

MenB & Manic

MenC

MenA

MenAC

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Institutional Sales

Others

Breakup by End User:

Pediatric

Adult

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Ltd. and Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report:

  • How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global meningococcal vaccines market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the composition?
  • What is the breakup of the market based on the vaccine serotype?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global meningococcal vaccines market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Meningococcal Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Conjugate
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polysaccharide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subcapsular
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Composition

  • 7.1 Mono Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combination Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Vaccine Serotype

  • 8.1 MenACWY
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MenB & Manic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 MenC
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 MenA
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 MenAC
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Institutional Sales
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pediatric
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Adult
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 GlaxoSmithKline Plc
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Hualan Biological Engineering Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Incepta Pharmaceuticals Limited
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Novartis AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Pfizer Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Sanofi S.A.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Serum Institute of India Ltd.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Walvax Biotechnology Co. Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials